Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000806 · ClinicalTrials.gov registry record · Phase 1

A Phase I Randomized Dose/Formulation Comparison Study of SC-52151

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
4
Study locations

NCT00000806: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000806 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000806, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
4
Study locations

Study Summary

PRIMARY: To evaluate the safety, tolerability, pharmacokinetics, and ethanol exposure of two dose regimens and formulations of SC-52151. SECONDARY: To evaluate the preliminary anti-HIV activity of these treatment regimens and the relationship between day 14 plasma concentrations of SC-52151 and immunological and virological markers and toxicity. Since viral isolates with decreased susceptibility to the protease inhibitor SC-52151 occur in vitro after multiple passages, and since prolonged post infectious effects occur in vitro, comparison of two formulations, an elixir and a self-emulsifying drug delivery system (SEDDS), is needed to determine the appropriate dose formulation for Phase II studies.

Conditions Studied

HIV Infections

Interventions

  • DRUG Telinavir

Study Locations (4)

California

  • Univ of California / San Diego Treatment Ctr - San Diego

Florida

  • Univ of Miami School of Medicine - Miami

Maryland

  • Johns Hopkins Hosp - Baltimore

Ohio

  • Ohio State Univ Hosp Clinic - Columbus

Trial Details

FieldValue
Enrollment Target 48 participants
Phase Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000806 record still lists

NCT00000806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Telinavir is the first listed.

NCT00000806 reports a single indexed study location in California, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT00000806 about?

NCT00000806 is a clinical study titled "A Phase I Randomized Dose/Formulation Comparison Study of SC-52151". PRIMARY: To evaluate the safety, tolerability, pharmacokinetics, and ethanol exposure of two dose regimens and formulations of SC-52151. SECONDARY: To evaluate the preliminary anti-HIV activity of these treatment regimens and the relationship between day 14 plasma concentrations of SC-52151 and imm...

What is the current status of trial NCT00000806?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants.

What conditions does trial NCT00000806 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000806?

The interventions under investigation include: Telinavir (DRUG).

Who is sponsoring clinical trial NCT00000806?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000806 being conducted?

This trial has 4 study locations across California, Florida, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000806's enrollment target sits among peer trials

48 367th of 542 higher than 168 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Related registry views

Source: ClinicalTrials.gov NCT00000806, the US trial registry maintained by the National Library of Medicine. NCT00000806 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.